157 results on '"Thiebaut-Bertrand, Anne"'
Search Results
2. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
3. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study
4. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)
5. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry
6. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC
7. Virus d’Epstein-Barr et syndromes lymphoprolifératifs post-transplantation
8. Early picc-line infections in non-neutropenic patients are mainly due to E. coli suggesting that third-generation cephalosporin may be used as a first-line antibiotic therapy
9. Inhibition of Voriconazole Metabolism by Meropenem : A Role for Inflammation?
10. Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)
11. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
12. Early picc-line infections in non-neutropenic patients are mainly due to E. coli suggesting that third-generation cephalosporin may be used as a first-line antibiotic therapy
13. P315: TP53 ALTERATIONS AND MRD REFINE PROGNOSIS OF ADULT KMT2A-REARRANGED B-ALL
14. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
15. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
16. Comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in hematological patients: a multicenter, prospective, cluster randomized, crossover clinical trial’
17. Added value of next-generation sequencing for multilocus sequence typing analysis of a Pneumocystis jirovecii Pneumonia outbreak
18. Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
19. In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial
20. Variability of Isavuconazole Trough Concentrations during Longitudinal Therapeutic Drug Monitoring
21. Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire
22. Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
23. The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study
24. Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2
25. IgG1 anti-cell wall and IgG2 anti-phosphopeptidomannan antibodies in the diagnosis of invasive candidiasis and heavy Candida colonization
26. Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation
27. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated
28. Minimum inhibitory concentrations of amphotericin B against Candida krusei isolates from a French teaching hospital laboratory: a retrospective study over 8 years
29. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
30. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
31. Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial
32. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations
33. Inflammation is a potential risk factor of voriconazole overdose in hematological patients
34. Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant
35. Early picc-line infections in non-neutropenic patients are mainly due to E. colisuggesting that third-generation cephalosporin may be used as a first-line antibiotic therapy
36. Risk Factors of BK Virus Cystitis in Haematopoietic Stem Cell Transplantation-a Retrospective Monocentric Study
37. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations
38. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
39. Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
40. Intérêt de la quantification des pseudo corps de Howell-Jolly dans les polynucléaires neutrophiles par l’analyseur CellaVision DM96 pour le diagnostic des toxicités hématologiques du ganciclovir
41. Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC
42. Quantification of Howell-Jolly body-like inclusions in ganciclovir toxicity using CellaVision DM96 analyser
43. Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels
44. Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties
45. Apport du séquençage nouvelle génération au typage MLST de Pneumocysits jirovecii, dans le cadre d’une épidémie chez des patients transplantés d’organe solide
46. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
47. Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital
48. Minimum inhibitory concentrations of amphotericin B against Candida krusei isolates from a French teaching hospital laboratory: a retrospective study over 8 years
49. Characteristics and clinical relevance of the quantitative touch-down major surface glycoprotein polymerase chain reaction in the diagnosis ofPneumocystispneumonia
50. Characteristic and clinical relevance of Candida mannan test in the diagnosis of probable invasive candidiasis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.